BEFORE THE LEGISLATIVE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON AGENDA

DATE: MONDAY, NOVEMBER 8, 2010

1 P.M.

BETH C. DRAIN, CSR CSR. NO. 7152 REPORTER:

BRS FILE NO.: 88675

INDEX

ITEM	DESCRIPTION	PAGE NO
CALL TO OF	RDER	3
ROLL CALL		3
	TION OF FEDERAL LEGISLATIVE ES REGARDING STEM CELL RESEARCH	4
PUBLIC COM	MMENT	25

2

	DARRISTERS REPORTING SERVICE
1	MONDAY, NOVEMBER 8, 2010; 1 P.M.
2	
3	CHAIRMAN TORRES: THE LEGISLATIVE
4	SUBCOMMITTEE WILL COME TO ORDER. WOULD YOU CALL THE
5	ROLL, PLEASE.
6	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
7	MICHAEL GOLDBERG.
8	MR. GOLDBERG: HERE.
9	MS. KING: BOB KLEIN.
10	CHAIRMAN KLEIN: HERE.
11	MS. KING: CLAIRE POMEROY. FRANCISCO
12	PRIETO.
13	DR. PRIETO: HERE.
14	MS. KING: JEANNIE FONTANA.
15	DR. FONTANA: HERE.
16	MS. KING: DUANE ROTH.
17	MR. ROTH: HERE.
18	MS. KING: JOAN SAMUELSON.
19	MS. SAMUELSON: HERE.
20	MS. KING: JEFF SHEEHY.
21	MR. SHEEHY: HERE.
22	MS. KING: ART TORRES.
23	CHAIRMAN TORRES: HERE.
24	MS. KING: THANK YOU. THANK YOU ALL THREE
25	OF YOU. WE DO HAVE A QUORUM PRESENT.
	2
	3

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

CHAIRMAN TORRES: ALL RIGHT. THERE'S A
QUORUM PRESENT. WE'D LIKE TO START FIRST WITH
HAVING OUR BIRTHDAY BOY ARTICULATE FOR US THE TWO
PIECES OF LEGISLATION THAT WE'RE AWARE OF AT THE
FEDERAL LEVEL THAT MAY OR MAY NOT BE INTRODUCED.
MR. HARRISON: THANK YOU, MR. CHAIR.
CHAIRMAN TORRES: SHOULD BE IN YOUR
PACKETS AS WELL, MEMBERS.
MR. HARRISON: AS YOU MAY KNOW, THERE ARE
TWO BILLS THAT HAVE BEEN INTRODUCED, HR 4808 BY
CONGRESSWOMAN DEGETTE AND S 3766 WHICH WAS
INTRODUCED BY SENATOR SPECTER. THESE BILLS WILL
PROBABLY BE FAMILIAR TO THOSE OF YOU WHO HAVE HAD A
CHANCE TO TAKE A LOOK AT THEM BECAUSE THEY ARE
SIMILAR TO TWO BILLS THAT WERE ADOPTED AND VETOED BY
PRESIDENT BUSH.
BRIEFLY THE DEGETTE BILL WOULD ESSENTIALLY
CODIFY PRESIDENT OBAMA'S EXECUTIVE ORDER TO LIFT
RESTRICTIONS ON FEDERAL FUNDING FOR HUMAN EMBRYONIC
STEM CELL RESEARCH PROVIDED THAT ETHICAL
REQUIREMENTS ARE SATISFIED. IT WOULD ALSO PROHIBIT
HUMAN REPRODUCTIVE CLONING.
THE SPECTER BILL IS SUBSTANTIALLY SIMILAR,
BUT IT GOES ONE STEP FURTHER BY EXPRESSLY AMENDING
THE DICKEY-WICKER AMENDMENT TO CLARIFY THAT
4

1	DICKEY-WICKER DOES NOT PROHIBIT FEDERAL FUNDING FOR
2	RESEARCH ON HUMAN EMBRYONIC STEM CELL LINES. THE
3	BILLS HAVE BEEN INTRODUCED, BUT NO ACTION HAS BEEN
4	TAKEN ON THEM AS YET.
5	SENATOR TORRES ALSO ASKED ME TO COMMENT
6	BRIEFLY ON THE LITIGATION THAT IS PENDING IN THE DC
7	CIRCUIT AND AT THE DISTRICT COURT THERE. AS YOU ALL
8	KNOW, THE DISTRICT COURT IN THE SHIRLEY VS. SEBELIUS
9	CASE ISSUED A PRELIMINARY INJUNCTION EARLY THIS FALL
10	PROHIBITING FEDERAL FUNDING ON HESC LINES. THE
11	DEPARTMENT OF JUSTICE IMMEDIATELY APPEALED THE
12	DISTRICT COURT'S ISSUANCE OF THE PRELIMINARY
13	INJUNCTION AND REQUESTED AN IMMEDIATE STAY. THE
14	COURT OF APPEAL RESPONDED BY ISSUING THE STAY AND
15	EXPEDITING ITS CONSIDERATION OF THE APPEAL.
16	ALL BRIEFING IS NOW COMPLETE, AND THE
17	COURT OF APPEALS HAS SCHEDULED ORAL ARGUMENT FOR
18	DECEMBER 6TH. SO WE CAN EXPECT THAT THE COURT OF
19	APPEAL WILL ISSUE A DECISION MOST LIKELY EARLY IN
20	2011.
21	MEANWHILE AT THE DISTRICT COURT THE
22	PARTIES HAVE FILED COMPETING SUMMARY JUDGMENT
23	MOTIONS. THOSE ARE PENDING, BUT THE DISTRICT COURT
24	HAS NOT YET SCHEDULED A HEARING DATE. IT'S LIKELY
25	THAT THE OF DISTRICT COURT IS WAITING FOR THE COURT

1	OF APPEAL FIRST TO RULE ON THE APPEAL FROM THE
2	PRELIMINARY INJUNCTION.
3	THE OUTCOME OF THE COURT OF APPEALS
4	DECISION WOULD BE SUBJECT TO A PETITION FOR CERTIORI
5	FILED BY EITHER PARTY TO THE U.S. SUPREME COURT. SO
6	IT'S LIKELY WE WILL NOT HAVE A FINAL DECISION IN
7	THIS MATTER FOR SOME TIME AS IT MAKES ITS WAY
8	THROUGH THE COURTS. SO THAT'S A BRIEF OVERVIEW.
9	CHAIRMAN TORRES: THANK YOU, MR. HARRISON.
10	AND CONGRATULATIONS AGAIN.
11	CHAIRMAN KLEIN: SENATOR TORRES, COULD I
12	ASK A QUESTION OF MR. HARRISON?
13	CHAIRMAN TORRES: YES, PLEASE, MR. KLEIN.
14	CHAIRMAN KLEIN: SO MY UNDERSTANDING,
15	JAMES, IS THAT THE DEGETTE BILL CITES AS ONE OF THE
16	HISTORICAL BACKGROUNDS THE JULY 7, 2009, INSTITUTE
17	OF HEALTH ETHICAL STANDARDS FOR HUMAN STEM CELL
18	RESEARCH AND DOES NOT OVERRIDE THOSE STANDARDS. SO
19	IF THIS BILL WERE ENACTED, EMBRYONIC STEM CELL
20	RESEARCH WOULD BE CARRIED ON AT THE NIH WITHIN THE
21	PARAMETERS OF THE NIH GUIDELINES THAT OBAMA HAS
22	SUPPORTED; IS THAT CORRECT?
23	MR. HARRISON: YES, THAT'S A CORRECT
24	STATEMENT.
25	CHAIRMAN KLEIN: I RAISE THAT ISSUE

6

1	BECAUSE, WITH GREAT RESPECT FOR JEANNIE FONTANA, WHO
2	WROTE A GREAT MEMO ABOUT POTENTIALLY EXPANDING TO
3	SCNT AND PARTHENOGENESIS, I THINK DUANE HAS
4	PREVIOUSLY MADE A GOOD POINT, WHICH IS FOR THE
5	AMERICAN PUBLIC IN A TIME WHICH IS POLITICALLY VERY
6	VOLATILE, OUR HIGHEST CHANCES OF SUCCESS WOULD BE TO
7	SUPPORT SOMETHING THAT'S WITHIN THE ETHICAL CONTEXT
8	AND PUBLICLY VETTED AND APPROVED TO DATE.
9	DR. FONTANA: I'D LIKE TO POINT OUT
10	SOME
11	CHAIRMAN TORRES: HOLD ON A SECOND. IS
12	THAT IT, BOB?
13	CHAIRMAN KLEIN: THAT'S IT. THANK YOU.
14	CHAIRMAN TORRES: YOU DON'T HAVE A MOTION?
15	CHAIRMAN KLEIN: I'D LIKE TO HEAR THE
16	DISCUSSION.
17	CHAIRMAN TORRES: ALL RIGHT. MICHAEL
18	GOLDBERG, AND THEN WE'RE GOING TO GO TO DR. FONTANA.
19	MR. GOLDBERG: I HAVE A QUESTION FOR
20	JAMES. AFTER THE APPELLATE DECISION COMES DOWN,
21	PRESUMABLY ONE PARTY WILL FILE FOR CERT IMMEDIATELY.
22	AND WHEN IS IT THAT THE SUPREME COURT WILL MAKE THE
23	DECISION, OR WILL WE KNOW WHETHER THE SUPREME COURT
24	WILL DECIDE WHETHER TO HEAR THE CASE? CAN THAT ALL
25	HAPPEN IN THE SPRING OF 2011?

1	MR. HARRISON: IT'S HIGHLY UNLIKELY IT
2	WOULD ALL HAPPEN IN THE SPRING OF 2011. IF THE
3	SUPREME COURT WERE TO TAKE THAT CASE, IT WOULD
4	LIKELY COME UP FOR ARGUMENT IN THE COURT'S NEXT
5	SESSION; IN OTHER WORDS, THE SESSION BEGINNING IN
6	OCTOBER OF 2011.
7	MR. GOLDBERG: RIGHT. BUT THEY WOULD MAKE
8	A DECISION.
9	MR. HARRISON: THEY WOULD MAKE A DECISION
10	WHETHER OR NOT TO HEAR THE CASE.
11	MR. GOLDBERG: AND THE VAST MAJORITY OF
12	CASES THEY DON'T TAKE.
13	MR. HARRISON: CORRECT. RIGHT.
14	MR. GOLDBERG: SO WE'LL KNOW THAT.
15	MR. HARRISON: WE SHOULD KNOW THAT IN THE
16	SPRING OF 2001.
17	CHAIRMAN TORRES: DR. FONTANA.
18	DR. FONTANA: I HAVE SOMEBODY FROM THE
19	PUBLIC COMING IN RIGHT NOW. BUT, JAMES, COULD YOU
20	HELP CLARIFY BECAUSE I AM BY NO MEANS AN ATTORNEY,
21	BUT HAVE SPENT QUITE A BIT OF TIME TRYING TO
22	UNDERSTAND BOTH THE LITIGATION AND THE LEGISLATION
23	ON THIS. SO, JAMES, MY UNDERSTANDING IS THAT BOTH
24	THE DEGETTE AND THE SPECTER BILLS ARE FRAUGHT WITH
25	INCONSISTENCIES WITH BOTH THE CURRENT NIH GUIDELINES

1	AND EVEN CODIFYING OBAMA'S EXECUTIVE ORDER.
2	COULD YOU HELP CLARIFY FOR EVERYBODY WHERE
3	THE FAULTS ARE THAT WOULD OPEN UP TO PERHAPS FUTURE
4	LITIGATION IF EITHER OF THESE BILLS GO THROUGH?
5	MR. HARRISON: WELL, LET ME TAKE A STAB AT
6	THAT. FIRST OF ALL, THE BILLS EXPRESSLY PROHIBIT
7	HUMAN REPRODUCTIVE CLONING. THAT EXPRESS
8	PROHIBITION DOES NOT EXTEND TO SCNT OR
9	PARTHENOGENESIS. BUT AS MR. KLEIN POINTED OUT, THE
10	BILLS ALSO REFERENCE AND INCORPORATE THE GUIDELINES
11	THAT PRESIDENT OBAMA ADOPTED PURSUANT TO HIS
12	EXECUTIVE ORDER IN 2009.
13	SO IN OTHER WORDS, THE NIH WOULD CONTINUE
14	TO OPERATE UNDER THE PRESIDENT'S EXISTING GUIDELINES
15	IF THE DEGETTE BILL WERE TO BE ENACTED.
16	I ALSO UNDERSTAND THAT A QUESTION HAS BEEN
17	RAISED ABOUT WHETHER THE DEGETTE BILL WOULD PERMIT
18	THE DERIVATION OF STEM CELL LINES. AS I READ IT, I
19	BELIEVE THAT IT WOULD NOT BE CONSTRUED TO PERMIT THE
20	DERIVATION OF STEM CELL LINES BECAUSE IT REFERS
21	SPECIFICALLY TO UTILIZING HUMAN STEM CELLS. SO AS I
22	UNDERSTAND IT, IT WAS NOT INTENDED TO GO BEYOND WHAT
23	THE NIH CURRENTLY PERMITS, WHICH IS RESEARCH ON
24	LINES THAT HAVE PREVIOUSLY BEEN DERIVED, BUT THAT'S
25	ONE QUESTION THAT I KNOW HAS COME UP.

1	DR. FONTANA: AND THEN, OF COURSE, THE
2	SPECTER BILL, WHICH SPECIFICALLY TRIES TO AMEND THE
3	DICKEY-WICKER AMENDMENT, AGAIN, CAN YOU TALK ABOUT
4	THE
5	MR. HARRISON: SURE. SO THE DEGETTE
6	BILL WELL, LET ME START WITH THE SPECTER BILL.
7	THE SPECTER BILL EXPRESSLY AMENDS THE DICKEY-WICKER
8	AMENDMENT. AS YOU ALL KNOW, THE DICKEY-WICKER
9	AMENDMENT IS A RIDER ATTACHED TO THE ANNUAL
10	APPROPRIATIONS BILL. SO THE SPECTER BILL AMENDS THE
11	2010 APPROPRIATIONS BILL TO CLARIFY THAT
12	DICKEY-WICKER DOES NOT PROHIBIT THE RESEARCH THAT
13	NIH IS CURRENTLY SUPPORTING.
14	THAT AMENDMENT, IF IT WERE ATTACHED TO
15	FUTURE APPROPRIATIONS BILLS, WOULD CLARIFY THINGS
16	GREATLY. HOWEVER, IF IN THE FUTURE DICKEY-WICKER
17	READ AS IT CURRENTLY DOES, THEN THE QUESTION WOULD
18	REMAIN OPEN, THE VERY QUESTION THAT IS NOW PENDING
19	IN THE COURT OF APPEALS, AS TO WHETHER DICKEY-WICKER
20	REACHES RESEARCH ON LINES THAT HAVE PREVIOUSLY BEEN
21	DERIVED.
22	SO PART OF THE CHALLENGE IS THAT, ONE,
23	CONGRESS CAN'T TIE THE HANDS OF A FUTURE CONGRESS.
24	SO ATTEMPTS TO PROHIBIT FUTURE LEGISLATION BY SAYING
2425	SO ATTEMPTS TO PROHIBIT FUTURE LEGISLATION BY SAYING NOTWITHSTANDING SUBSEQUENT LEGISLATION GENERALLY

1	AREN'T EFFECTIVE. CONGRESS WOULD HAVE TO EITHER
2	INCLUDE THE SPECTER LANGUAGE IN FUTURE
3	APPROPRIATIONS BILL'S BILL RIDERS OR THIS QUESTION
4	COULD COME UP AGAIN.
5	THE DEGETTE BILL DOES NOT TAKE ON
6	DICKEY-WICKER DIRECTLY. IT DOES ARGUABLY IMPLICITLY
7	ADDRESS IT BECAUSE IT HAS A NOTWITHSTANDING CLAUSE.
8	SO IF DICKEY-WICKER WERE CONSTRUED TO PROHIBIT SUCH
9	RESEARCH, THE DEGETTE BILL, I THINK, WOULD BE FOUND
10	TO BE AN IMPLICIT REPEAL OF THAT LIMITATION.
11	AGAIN, IN THE FUTURE WHAT WOULD HAPPEN
12	WOULD DEPEND UPON CONGRESSIONAL ACTION.
13	DR. PRIETO: DO EITHER OF THESE BILLS HAVE
14	ANY OF THE REPUBLICAN COSPONSORS THAT THEY HAD WHEN
15	THEY WERE ORIGINALLY INTRODUCED OR WHEN THE ORIGINAL
16	VERSIONS WERE INTRODUCED?
17	MR. HARRISON: THE DEGETTE BILL HAS
18	CONGRESSMEN CASTLE AS A COSPONSOR AND SEVERAL OTHER
19	COSPONSORS. I DON'T KNOW HOW MANY OF THEM ARE
20	REPUBLICANS.
21	DR. PRIETO: AND THE SPECTER BILL?
22	CHAIRMAN TORRES: MRS. BOXER, MRS.
23	FEINSTEIN ARE THE ONLY TWO THAT I HAVE LISTED IN
24	FRONT OF ME.
25	DR. PRIETO: OKAY. IT JUST SEEMS THAT

1	THERE WOULD BE SOME POTENTIAL LIKE SENATOR HATCH WHO
2	MIGHT SIGN ON.
3	CHAIRMAN TORRES: AGAIN, THIS DISCUSSION
4	IS ALL SPECULATIVE BECAUSE THIS SESSION WILL NOT
5	RECONVENE UNTIL NOVEMBER 15TH, AND IT'S CLEAR FROM
6	THE DISCUSSIONS THAT I'VE HAD WITH A NUMBER OF U.S.
7	SENATORS AND MEMBERS OF CONGRESS THAT THIS ISSUE
8	MAY NOT EVEN COME UP IN THE LAME DUCK SESSION. THAT
9	DOESN'T PRECLUDE US FROM TAKING A POSITION IN AN
10	AREA WHICH WE THINK IS APPROPRIATE MUCH IN THE SAME
11	WAY THAT ON NOVEMBER 5TH, THIS FRIDAY, DEANS OF
12	MEDICAL SCHOOLS, ALL OF WHOM ARE ON OUR BOARD, AS
13	WELL AS OTHER SCIENTISTS SENT A LETTER OF SUPPORT
14	FOR THE DEGETTE LEGISLATION AND SPECTER LEGISLATION
15	TO LEADERSHIP IN BOTH HOUSES.
16	CHAIRMAN KLEIN: SENATOR TORRES, COULD I
17	MAKE A COMMENT ABOUT THAT?
18	CHAIRMAN TORRES: YES.
19	CHAIRMAN KLEIN: THIS IS BOB KLEIN. AND I
20	THINK IT IS EXTREMELY MATERIAL THAT DEANS OF MEDICAL
21	SCHOOLS AND HEADS OF RESEARCH INSTITUTES ACROSS THIS
22	COUNTRY HAVE STOOD UP PUBLICLY AND USED THEIR
23	TITLES, EVIDENTLY WITH THE BACKING OF THEIR
24	INSTITUTIONS, TO SUPPORT STEM CELL RESEARCH. THAT
25	IS AN EXTREMELY IMPORTANT NATIONAL EVENT FOR US.
	13

1	AND I BELIEVE IT WOULD BE VERY IMPORTANT FOR US TO
2	SHOW SOLIDARITY WITH THEM AT THIS TIME EVEN IF THESE
3	BILLS DO NOT COME UP IN THE CONGRESSIONAL SESSION.
4	BECAUSE WE'VE ASKED FOR THE SCIENTIFIC LEADERSHIP IN
5	THIS COUNTRY TO STAND UP AND DEFEND THE SCIENCE ON
6	PRINCIPLE FOR WHAT IS THE BROADEST INVESTIGATION
7	ACROSS THE STEM CELL AREA TO ENHANCE THE POTENTIAL
8	TO FIND NEW THERAPIES, THEY'RE DOING THIS. AND IT
9	CRIES OUT FOR OUR SUPPORT OF THEIR EFFORT.
10	DR. FONTANA: I'D LIKE TO MAKE A COMMENT
11	TOO ON THAT.
12	CHAIRMAN KLEIN: AND I WOULD SUGGEST THAT
13	WHILE IN THE SENATE IT MAY BE DIFFICULT TO BRING
14	THIS UP, IN THE HOUSE FOR THE MOMENT THE INDIVIDUALS
15	ARE STILL THERE WHO PREVIOUSLY VOTED TO PASS
16	LEGISLATION FOR EMBRYONIC STEM CELL RESEARCH TWICE
17	DURING THE BUSH ADMINISTRATION. SO I WOULD THINK
18	THERE MAY BE A REASONABLE OPPORTUNITY THAT THE HOUSE
19	WILL, EVEN THOUGH THEY HAVE AN EXTRAORDINARILY
20	JAMMED SESSION, BE ABLE TO BRING IT UP.
21	CHAIRMAN TORRES: DR. FONTANA HAD A
22	COMMENT.
23	DR. FONTANA: I DID. AND THANK YOU, BOB,
24	BECAUSE YOU REALLY ARE THE ICON OF THE PATIENT
25	ADVOCACY MOVEMENT. AND ALTHOUGH YOU REFERRED

1	SPECIFICALLY TO THE DEANS OF OUR ACADEMIC
2	INSTITUTIONS ACROSS OUR COUNTRY, I THINK IT REFLECTS
3	ON THIS GROUNDSWELL, THIS GRASS ROOTS MOVEMENT OF
4	MANY GROUPS THAT I HAVE SPOKEN TO THAT THEY
5	DESPERATELY WANT TO DO SOMETHING. AND THEY ARE
6	LOOKING TO CIRM TO BE THE LEADERS, AND THAT WE
7	HAVEN'T MADE A POSITION STATEMENT YET IS ALMOST LIKE
8	THE TRAIN HAS LEFT THE STATION AND WHERE ARE WE.
9	THEY'RE LOOKING FOR US. I THINK WE OWE THE COUNTRY
LO	A LEADERSHIP ROLE.
L1	AND I'D LIKE TO TAKE IT ONE STEP FURTHER
L2	AND SAY I THINK THAT BOTH BILLS ARE FRAUGHT WITH
L3	SOME INCONSISTENCIES. AND ALTHOUGH THEY HAVE BEEN
L4	PASSED IN BOTH CONGRESSES BEFORE, I THINK THE REAL
L5	ELEPHANT IN THE ROOM IS THE DICKEY-WICKER AMENDMENT.
L6	I THINK IT'S TIME TO CHANGE THE TERMS OF THE DEBATE
L7	AND THAT WE SHOULD ADDRESS THE DICKEY-WICKER
L8	AMENDMENT. AND I DON'T THINK THAT THERE'S ANY
L9	REASON WHY WE SHOULDN'T BECAUSE BY RESTATING OUR
20	MISSION STATEMENT WHERE WE SUPPORT HUMAN EMBRYONIC
21	STEM CELL RESEARCH THROUGH THE DERIVATION OF CELL
22	LINES FROM IVF EMBRYO DISCARD THAT WOULD OTHERWISE
23	BE DISCARDED, SCNT, PARTHENOGENESIS, THAT WE SUPPORT
24	THIS KIND OF RESEARCH AND WE SUPPORT THE LEGISLATION
25	THAT REFLECTS THIS. BECAUSE WE DON'T KNOW WHICH

1	BILL IS GOING TO MAKE IT THROUGH THE HOUSE OR THE
2	SENATE OR EVEN THESE TWO BILLS THAT ARE THERE, IT
3	MIGHT BE SOMETHING DIFFERENT. BUT I THINK IT SETS A
4	STANDARD, A REFERENCE FROM WHICH THE ADVOCATES AND
5	THE ACADEMIC COMMUNITY CAN GET BEHIND.
6	MS. SAMUELSON: ISN'T THAT IN PROP 71? IF
7	THAT'S IN PROP 71, THEN WE ALSO HAVE PEOPLE IN THE
8	STATE OF CALIFORNIA.
9	DR. FONTANA: ABSOLUTELY.
10	CHAIRMAN KLEIN: WHAT'S IN PROP 71?
11	MS. SAMUELSON: THAT'S WHAT I WAS ASKING,
12	IF THAT LANGUAGE WAS IN THE INITIATIVE BECAUSE IT'S
13	MORE THAN JUST US. IT'S THE PEOPLE.
14	CHAIRMAN TORRES: RIGHT.
15	MR. ROTH: SO I'M OBVIOUSLY VERY
16	SUPPORTIVE OF US WEIGHING IN ON SOMETHING, BUT I DO
17	WANT TO CAUTION EVERYONE THAT THE DEANS LETTER, THE
18	BIGGEST PROBLEM WITH THE DEANS LETTER IS THAT THEY
19	WANT TO DO IT IN LAME DUCK SESSION. AND TO EVERYONE
20	ON THE REPUBLICAN SIDE, THAT'S GOING TO SOUND LIKE,
21	HEY, LOOK. WE WANT TO QUICK PASS THIS BEFORE THE
22	REPUBLICANS COME IN AND DERAIL IT. AND IF YOU TAKE
23	THAT APPROACH, I'M ALMOST POSITIVE YOU'RE NOT GOING
24	TO GET ANY REPUBLICAN SUPPORT.
25	IF, ON THE OTHER HAND, YOU DECIDE THAT YOU

1	ALREADY HAD A LOT OF REPUBLICAN SUPPORT ON THE TWO
2	BILLS THAT BUSH VETOED AND YOU BUILD YOUR COALITION
3	FOR THE NEW CONGRESS AND GET THEM TO COME FORWARD
4	WITH THEIR AMENDMENT, WHATEVER IT IS, IN A WAY THAT
5	EVERYBODY HAS HAD A CHANCE TO SEE THE LIGHT OF DAY
6	ON, YOU HAVE A MUCH BETTER CHANCE OF FIXING THIS
7	DOWN THE ROAD. BUT I THINK IF YOU TRY TO RUSH IT
8	THROUGH LIKE, OKAY, THE BAD GUYS ARE COMING IN, AND
9	WE GOT TO QUICK PASS THIS, THAT'S NOT GOING TO WORK.
10	THEY'LL DELAY IT, AND THEN YOU RUN THE RISK OF
11	SOMETHING I DON'T THINK IS VERY CONTROVERSIAL RIGHT
12	NOW OF MAKING IT CONTROVERSIAL. AND THAT'S SO I
13	JUST CAUTION. THIS IS ABOUT STRATEGY.
14	IT'S NOT REALLY ABOUT WHETHER WE NEED TO
15	WEIGH IN ON ANYTHING TO DO WITH WHOSE BILL WE'RE
16	GOING TO SUPPORT, BUT, IN FACT, START BUILDING A
L 7	COALITION OF REPUBLICANS WHO WILL SIGN ON BECAUSE
18	THEY BELIEVE WHAT WE'RE DOING IS THE RIGHT THING. I
19	JUST DON'T WANT TO THROW DOWN A PROBLEM IN FRONT OF
20	THEM THAT'S NOT A REAL PROBLEM. I'M GOING TO GO
21	BACK ON MUTE.
22	CHAIRMAN KLEIN: SO, DUANE, I'D LIKE TO
23	HEAR FROM ART, BUT I'D LIKE TO REALLY EMPHASIZE IT.
24	THE WAY I LOOK AT THE VOTE COUNT AND THE POSITIONS
25	OF THOSE PEOPLE THAT GOT ELECTED FROM THE TEA PARTY

Т	MOVEMENT IN THE REPUBLICAN PARTY, ALTHOUGH THERE ARE
2	SUPPORTIVE MEMBERS OF THE REPUBLICAN PARTY, I DON'T
3	SEE THEM BEING ABLE IN CAUCUS TO BE ABLE TO BRING
4	THIS TO THE HOUSE IN THE NEXT TWO YEARS WITH A BILL
5	THAT WOULD SUPPORT EMBRYONIC STEM CELL RESEARCH.
6	THE NUMBERS JUST AREN'T THERE.
7	SO WHILE I APPLAUD THOSE PEOPLE IN THE
8	REPUBLICAN PARTY THAT HAVE STOOD UP FOR THE RIGHT
9	SOLUTION FOR MEDICAL RESEARCH AND SCIENTIFIC
10	RESEARCH IN GENERAL OF NOT HAVING IDEOLOGY DICTATE
11	THE OUTCOME, I DON'T THINK THE VOTES ARE IN THE
12	CAUCUS TO BRING IT THE FLOOR. SO SUPPORTING THE
13	BILL FOR THE PEOPLE WHO HAVE CHAMPIONED THIS IN THE
14	LAST FEW YEARS AND SUPPORTING THE SCIENTIFIC
15	LEADERSHIP ACROSS THE COUNTRY THAT'S COME FORWARD AT
16	THIS POINT I THINK IS VERY IMPORTANT.
17	BUT, ART, WHAT IS SENATOR TORRES, WHAT
18	IS YOUR VIEW?
19	CHAIRMAN TORRES: MY VIEW IS TWOFOLD. NO.
20	1, AND THIS IS NOT A POLITICAL STATEMENT, BUT I
21	AGREE WITH BOTH OF THE STATEMENTS THAT HAVE BEEN
22	MADE, BOTH DUANE AND YOUR COMMENTS. I THINK THAT AT
23	THE END OF THE DAY, WE CAN PUT FORWARD A RESOLUTION
24	FROM CIRM THAT IS NOT ADVERSARIAL TO THE
25	REPUBLICANS, BUT MERELY STATES OUR SUPPORT FOR A

1	CONCEPT WHICH IS INHERENT IN OUR INITIATIVE, WHICH
2	THE VOTERS OF THIS STATE CAPITULATED AND SUPPORTED.
3	ON THE OTHER HAND, IT DOESN'T PRECLUDE US
4	FROM FORMING A COALITION IN THE NEW CONGRESS, IF
5	THAT'S POSSIBLE, ON THIS ISSUE. TAKING THE FIRST
6	ELEMENT, WHICH IS WHAT'S IN FRONT OF US TODAY ARE
7	THESE TWO PIECES OF LEGISLATION, WE DON'T KNOW
8	WHETHER THEY'LL BE BROUGHT UP AT ALL OR IF IN THE
9	HOUSE WHETHER THEY'LL BE BROUGHT UP AT ALL. THAT
10	REMAINS TO BE SEEN.
11	I DO THINK THAT, AS DR. FONTANA SAID AND
12	OTHERS HAVE SAID, AND, AGAIN, I WANT TO THANK DR.
13	LOMAX FOR HIS HELP IN THIS PROCESS AS WELL AS ELONA
14	AND ALAN TROUNSON AND IAN SWEEDLER IN THEIR INPUT AS
15	WELL, THAT WE HAVE AN OPPORTUNITY HERE TO SHOW THE
16	PATIENT ADVOCACY GROUPS THAT WE ARE A LEADER ON THIS
17	ISSUE AND WE DO NEED TO EMBRACE WHATEVER IS BEFORE
18	THE CONGRESS TODAY BUT ALSO TOMORROW. SO I THINK IF
19	THERE'S ANY MOTION THAT COMES OUT OF THIS
20	SUBCOMMITTEE, IT OUGHT TO BE A MOTION TO SUPPORT
21	S 3766 AND HR 4808, BUT ALSO, IN ADDITION THERETO,
22	COME UP WITH A STATEMENT THAT WE HAD TALKED ABOUT
23	PREVIOUSLY WHICH GOES TO DUANE'S POINT.
24	AND THAT IS, AND JOAN'S AS WELL, THAT
25	IS WELL, THESE ARE TWO PIECES OF LEGISLATION, BUT

1	SUPPORT BEYOND THESE BILLS TO MOVE THIS BEYOND WHAT
2	IS ENACTED HERE INTO THE NEXT CONGRESS. UNLESS WE
3	GET APPROPRIATIONS IN THE NEXT CONGRESS, WE CAN PASS
4	A LOT OF THINGS, BUT THE APPROPRIATIONS PROCESS CAN
5	BE USED TO STRANGLE THE NIH'S ABILITY TO REALLY
6	CARRY OUT THE FUNDING.
7	CHAIRMAN TORRES: IS THERE A SECOND?
8	DR. FONTANA: I SECOND.
9	CHAIRMAN TORRES: SECOND BY DR. FONTANA.
10	AGAIN, JEANNIE, THANK YOU FOR ALL THE WORK YOU'VE
11	PUT IN OVER THE LAST FEW WEEKS. I KNOW IT'S BEEN
12	QUITE BURDENSOME, BUT IT'S A MISSION YOU UNDERTOOK
13	SO ELEGANTLY.
14	CHAIRMAN KLEIN: I'M SORRY, JEANNIE, THAT
15	I HAVEN'T BEEN ABLE TO CALL YOU AND TALK TO YOU
16	ABOUT WHAT YOU'VE DONE BECAUSE YOU'VE PUT A LOT OF
17	WORK INTO TO.
18	CHAIRMAN TORRES: WE HAVE A MOTION AND A
19	SECOND. NOW WE'RE READY FOR DISCUSSION. MEMBERS?
20	MS. SAMUELSON: QUICK COMMENT BY JOAN. I
21	THINK IT'S IMPORTANT THAT WE DO THIS, AND I AGREE
22	WITH EVERYTHING THAT'S BEEN SAID ABOUT WHY. I ALSO
23	THINK THAT THIS GIVES US A GREAT OPPORTUNITY TO MAKE
24	A POINT THAT I THINK WE MAKE BEST OF ANYBODY, WHICH
25	IS THE IMPACT ON PATIENTS OF THIS SLOWING DOWN AGAIN

1	OF THIS AREA OF RESEARCH AND TO MAKE THE POINT THAT
2	WE WILL NOW AGAIN BE THE ONLY GAME IN TOWN, WHICH IS
3	GREAT. THANK YOU, CALIFORNIA. BUT WE CAN'T
4	POSSIBLY MAKE THE STRIDES WE COULD IF WE WERE
5	COLLABORATING WITH THE PEOPLE ALL OVER THE COUNTRY
6	AND BEYOND THAT WE WOULD HAVE AT OUR SIDES IF WE HAD
7	NIH FUNDING.
8	PEOPLE NEED TO UNDERSTAND THAT SOMEHOW
9	THINGS AREN'T JUST BRIGHT AND HAPPY IN CALIFORNIA
10	AND WHAT THIS IS DOING TO PEOPLE, TO SICK AMERICANS.
11	CHAIRMAN TORRES: THANK YOU, JOAN.
12	MR. ROTH: I JUST WANT TO CLARIFY
13	UNDERSTAND THE MOTION AND THE SECOND. WE'RE NOT
14	GOING TO BE PUSHING FOR THE LAME DUCK ACTION; IS
15	THAT CORRECT?
16	DR. FONTANA: I THINK WE'RE SUPPORTING IT.
17	CHAIRMAN KLEIN: WE'RE SUPPORTING BOTH
18	THESE BILLS. IF THEY CAN GET THROUGH IN THE LAME
19	DUCK SESSION, FINE; BUT WE'RE ALSO ASKING FOR A
20	SEPARATE STATEMENT THAT CALLS UPON THE CONGRESS TO
21	CREATE A BIPARTISAN LEADERSHIP FOR THIS IN THE NEXT
22	CONGRESS WITH FUNDING THAT CAN REALLY MAKE THIS
23	RESEARCH GIVE THIS RESEARCH LIFE TO REACH THESE
24	PATIENTS, AS JOAN SAYS, WHO DESPERATELY NEED THESE
25	THERAPIES AND WITHOUT

T	MR. ROTH: I UNDERSTAND ALL THAT. BUT MY
2	VERY SPECIFIC QUESTION IS HOW HARD ARE WE GOING TO
3	PUT IN THE LETTER OR WHATEVER THE RECOMMENDATION IS
4	ABOUT LAME DUCK SESSION BECAUSE I THINK THAT'S WHERE
5	WE CAN END UP HURTING OURSELVES BADLY. ART SAID IT
6	RIGHT. I THINK THE CHANCES OF IT BEING ENACTED IN
7	LAME DUCK ARE VERY SMALL; AND IF WE MAKE TOO BIG A
8	DEAL OUT OF IT, WE'RE GOING TO END UP REALLY MAKING
9	OUR JOB MUCH HARDER IN THE NEW CONGRESS. SO I JUST
LO	WANT TO MAKE SURE WE DON'T DO THAT IF AT ALL
L1	POSSIBLE.
L2	CHAIRMAN KLEIN: DUANE, IF WE SUPPORT BOTH
L3	OF THESE BILLS, WE DON'T HAVE TO MENTION THE LAME
L4	DUCK SESSION.
L5	MR. ROTH: GOOD. THAT'S THE POINT I WANT
L6	TO MAKE, THAT WHILE WE CAN DO THAT, IF YOU THINK
L7	IT'S IMPORTANT, WE CAN DO THAT BEHIND THE SCENES TO
L8	TRY AND CONVINCE PEOPLE TO GET IT ON THE FLOOR, BUT
L9	LET'S NOT MAKE OUR JOB REALLY HARD BECAUSE WE TRY TO
20	RAILROAD SOMETHING THROUGH AND THEN IT GETS STALLED
21	AND EVERYBODY GOES, WHY IN THE HELL ARE YOU GUYS
22	DOING THIS. AND IT WILL BE A LONG TIME BEFORE WE
23	CAN TAKE IT UP IN THE NEW CONGRESS. THAT'S ALL. I
24	JUST WANTED TO MAKE SURE THAT WE DON'T PUSH TOO
25	HARD, THAT WE'RE TRYING TO

1	CHAIRMAN KLEIN: DUANE, JUST TO BE CLEAR,
2	IF, IN FACT, THEY DO BRING IT UP IN THE LAME DUCK
3	SESSION, WE'RE GOING TO BE SUPPORTIVE OF IT.
4	MR. ROTH: ABSOLUTELY. I'LL HELP, BUT WE
5	NEED REPUBLICAN VOTES TO GET THAT DONE, BUT THEY'LL
6	USE MANEUVERING AND OTHER THINGS TO DELAY IT.
7	THAT'S THE PROBLEM IS DON'T CUT OFF OUR OPPORTUNITY
8	TO BRING SOME REPUBLICANS IN.
9	CHAIRMAN KLEIN: OKAY.
10	CHAIRMAN TORRES: WE DEFINITELY NEED THEM
11	IN THE NEW CONGRESS, THAT'S FOR SURE. ARE THERE ANY
12	PUBLIC MEMBERS THAT WISH TO MAKE A STATEMENT AT THE
13	KLEIN FINANCIAL CORPORATION?
14	CHAIRMAN KLEIN: NO.
15	CHAIRMAN TORRES: ANYBODY IN DR. FONTANA'S
16	OPERATION?
17	DR. BRYANT: I LOGGED IN LATE. I JUST
18	WANTED TO LET YOU KNOW I'M HERE.
19	CHAIRMAN TORRES: ARE YOU WITH JEANNIE?
20	DID YOU HAVE A COMMENT, DR. BRYANT?
21	DR. BRYANT: I COMPLETELY AGREE WITH
22	EVERYTHING THAT PEOPLE HAVE BEEN SAYING. I THINK
23	IT'S VERY IMPORTANT FOR CIRM TO SPEAK OUT NOW, BUT I
24	THINK THE POLITICAL CONSIDERATIONS THAT DUANE
25	MENTIONED ARE VERY IMPORTANT. AND WE DON'T WANT TO
	22

1	BE OVERENTHUSIASTIC AND RUIN OUR CHANCES IN THE LONG
2	RUN IN GETTING THESE PASSED.
3	CHAIRMAN TORRES: DR. FONTANA, IS THERE A
4	PUBLIC COMMENT AT YOUR LOCATION?
5	DR. FONTANA: YES, THERE IS.
6	MS. KING: THE GENTLEMAN'S NAME IS GRANT
7	ALBRECHT. I BELIEVE YOU'VE MET HIM BEFORE. FIRST
8	NAME G-R-A-N-T, LAST NAME A-L-B-R-E-C-H-T; IS THAT
9	CORRECT?
10	MR. ALBRECHT: YES. AND FIRST OF ALL,
11	THANK YOU ALL FOR YOUR EFFORTS AND DILIGENCE ON
12	THIS. IT SEEMS TO ME THAT THE TIME TO ACT IS
13	DEFINITELY NOW WHETHER OR NOT WE CAN MAKE THE LAME
14	DUCK SESSION QUACK OR NOT. BECAUSE OF THE
15	LITIGATION, THE LEGISLATION IS CLEARLY SOMETHING WE
16	NEED TO TAKE CIRM NEEDS TO TAKE A POSITION ON,
17	BUT THE LITIGATION IS DEFINITELY COMING UP RATHER
18	IMMEDIATELY. AND AS IT MAY MAKE IT ALL THE WAY TO
19	THE SUPREME COURT, IT SEEMS TO ME THAT THE STATEMENT
20	OF PRINCIPLE THAT WE MAKE NEEDS TO BE ENOUGH THAT IT
21	CAN THEREBY BE A REFERENCE POINT FOR WHATEVER
22	LITIGATION COMES UP SO THAT WE CAN MAKE IT SEEMS
23	TO ME WE'RE THE LEADERS, AND WE NEED TO MAKE WE
24	NEED TO BE REFERENCE FOR BOTH LITIGATION AND
25	LEGISLATION THAT MAY COME UP SOONER OR LATER.
	2.4

1	
1	CHAIRMAN TORRES: THANK YOU VERY MUCH.
2	ANYONE ELSE THERE AT DR. FONTANA'S OFFICE?
3	DR. FONTANA: NO.
4	CHAIRMAN TORRES: ALL RIGHT. WE MOVE TO
5	HEALDSBURG.
6	MS. SAMUELSON: NO PUBLIC COMMENT HERE.
7	CHAIRMAN TORRES: NO PUBLIC COMMENT, NO
8	WINE TASTING, NOTHING.
9	MS. SAMUELSON: THAT'S THE PROBLEM. WE
10	COULD CHANGE THAT.
11	CHAIRMAN TORRES: ELK GROVE.
12	DR. PRIETO: NONE HERE.
13	CHAIRMAN TORRES: NONE THERE. UC IRVINE,
14	ANYONE THERE?
15	DR. BRYANT: NO.
16	CHAIRMAN TORRES: DUANE, DO YOU HAVE
17	ANYBODY AT CONNECT?
18	MR. ROTH: NO.
19	CHAIRMAN TORRES: HERE IN SAN FRANCISCO WE
20	HAVE THE VENERABLE HONORABLE DON REED.
21	MR. REED: I'VE BEEN SPENDING A LOT OF
22	TIME WITH PATIENT ADVOCATES GROUPS. I THINK THIS IS
23	VERY IMPORTANT WHAT YOU ARE AGREEING TO DO. WE NEED
24	A RINGING ENDORSEMENT, A REMINDER OF WHY WE FIGHT.
25	THIS IS A LONG AND DIFFICULT BATTLE, AND WE NEED
	25

1	SOMETHING SHINING TO SHOOT FOR. CALIFORNIA DID
2	EVERYTHING RIGHT, AND WE NEED TO REMIND AMERICA OF
3	WHAT'S AT STAKE.
4	ALSO, I THINK IT'S IMPORTANT THAT WE
5	MENTION THE IMPORTANCE OF JOBS, MENTION THAT
6	CALIFORNIA ACTUALLY HAD TO PASS A LAW TO ENSURE THAT
7	THERE WOULD BE WORKERS TO MEET THE DEMAND FOR THIS
8	NEW ENTERPRISE. THIS KIND OF HOPEFULNESS FOR JOBS
9	IS NOT COMMON IN THE COUNTRY AND THEY NEED TO BE
10	REMINDED HOW IMPORTANT THIS IS. I THINK THE
11	NATIONAL DEFICIT HAS TO BE MENTIONED BECAUSE EVEN
12	THE MOST DIFFERENT INDIVIDUALS THAT ARE COMING TO
13	FACE THEY'RE INEXPERIENCED. THEY ALL WANT THE
14	NATIONAL DEBT MET. AND WITH 1.65 TRILLION LAST
15	YEAR'S COST FOR INCURABLE DISEASES OUTSTRIPPING THE
16	ACTUAL NATIONAL DEFICIT OF 1.6 TRILLION AND FAR
17	EXCEEDING THE TOTAL FEDERAL INCOME TAX AT 1.2
18	TRILLION, WE HAVE A TREMENDOUS CONTRIBUTION TO BRING
19	THAT DEFICIT DOWN, AND THAT NEEDS TO BE PART OF THE
20	PACKAGE. THOSE ARE MY THOUGHTS.
21	CHAIRMAN TORRES: THANK YOU, MR. REED.
22	ANY OTHER COMMENTS HERE IN SAN FRANCISCO? ANY OTHER
23	COMMENTS AT ANY OTHER LOCATION?
24	CHAIRMAN KLEIN: JUST, SENATOR TORRES, I
25	THINK GRANT'S COMMENT IS IMPORTANT HERE THAT IN

1	TERMS OF OUR STATEMENT, I WOULD ASK YOU AS CHAIR
2	PERHAPS IN WORKING WITH OUR OUTSIDE COUNSEL, WHEN WE
3	MAKE OUR STATEMENT, IF WE COULD REFERENCE BACK EVEN
4	TO THE BUSH ADMINISTRATION'S BELIEF THAT THEY COULD
5	FUND CONSISTENT WITH DICKEY-WICKER AS WELL AS THE
6	OBAMA ADMINISTRATION FOLLOWING THAT TEMPLATE SO THAT
7	WE REALLY POSITION THE HISTORY IN ALLOWING THIS
8	CURRENT FUNDING TO GO FORWARD AS PART OF OUR
9	STATEMENT IN A BIPARTISAN HISTORY WITH A SIMILAR OR
10	NEARLY IDENTICAL INTERPRETATION OF DICKEY-WICKER.
11	CHAIRMAN TORRES: ALL RIGHT. I'M GOING TO
12	ASK OUR COUNSEL TO RESTATE THE MOTION.
13	MR. HARRISON: THE MOTION, AS I UNDERSTAND
14	IT, IS TO SUPPORT BOTH BILLS WITHIN THE CONTEXT OF
15	THE NIH GUIDELINES ADOPTED JULY 7, 2009, AND TO
16	DEVELOP A STATEMENT OF PRINCIPLES, INCLUDING A
17	SPECIFIC CALL FOR BIPARTISAN SUPPORT TO ADVANCE STEM
18	CELL RESEARCH IN THE NEXT CONGRESS.
19	CHAIRMAN TORRES: ALL RIGHT. THE MOTION
20	IS BEFORE US. PLEASE CALL THE ROLL.
21	DR. FONTANA: I WANT TO MAKE A
22	CLARIFICATION ABOUT THAT. THE SECOND PART OF THAT
23	MOTION, I JUST WANT TO MAKE SURE, SINCE WE'RE BEING
24	SPECIFIC, THAT WE CLARIFY WITHIN THAT OUR MISSION
25	STATEMENT THAT SPECIFICALLY SUPPORTS HUMAN EMBRYONIC

1	STEM CELL RESEARCH AND ALL FORMS OF IT.
2	CHAIRMAN TORRES: SO NOTED. CALL THE
3	ROLL, PLEASE.
4	MS. KING: SUSAN BRYANT.
5	DR. BRYANT: YES.
6	MS. KING: MICHAEL GOLDBERG.
7	MR. GOLDBERG: YES.
8	MS. KING: BOB KLEIN.
9	CHAIRMAN KLEIN: YES.
10	MS. KING: FRANCISCO PRIETO.
11	DR. PRIETO: AYE.
12	MS. KING: JEANNIE FONTANA.
13	DR. FONTANA: YES.
14	MS. KING: DUANE ROTH.
15	MR. ROTH: YES.
16	MS. KING: JOAN SAMUELSON.
17	MS. SAMUELSON: YES.
18	MS. KING: JEFF SHEEHY.
19	MR. SHEEHY: YES.
20	MS. KING: ART TORRES.
21	CHAIRMAN TORRES: AYE.
22	MS. KING: FOR THE RECORD THE MOTION
23	CARRIES.
24	CHAIRMAN TORRES: THE MOTION CARRIES. ANY
25	OTHER BUSINESS BEFORE THE SUBCOMMITTEE?
	28

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. SAMUELSON: JUST A THOUGHT I'D LIKE US
2	TO THINK ABOUT LATER. THE HUNTINGTON'S COMMUNITY
3	MAKE SUCH AN INCREDIBLE IMPACT ON US AS A BOARD WHEN
4	THEY COME TO THE MIC. IF THEY COULD BE ENCOURAGED
5	TO BE ACTIVE IN AN EFFORT ON THE HILL, I THINK
6	THEY'D HAVE A HUGE IMPACT. I'M JUST IMAGINING THEM
7	AND MR WHAT'S HIS NAME, THE FUTURE SPEAKER?
8	BOEHNER AND OTHERS AND THOSE WHO HAVE BEEN OUR
9	FRIENDS AT TIMES AND WHO ARE UNDER TERRIBLE PRESSURE
LO	ON THIS LIKE FRED UPTON WHO IS, I GUESS, GOING TO BE
L1	THE CHAIRMAN OF THE ENERGY, I CAN'T THINK OF THE
L2	NAME, BUT HE WILL HAVE ENORMOUS POWER. HE'S RIGHT
L3	ON THE FENCE AND HE'S BEEN THERE A FAIR AMOUNT AND
L4	IT'S DIFFICULT FOR HIM. WHEN THEY GET ADVOCATES IN
L5	THEIR OFFICES AND THEY CAN USE THAT TO SAY, LOOK, I
L6	HAD NO CHOICE. AND THOSE FOLKS COULD BE EXTREMELY
L7	EFFECTIVE.
L8	CHAIRMAN TORRES: RIGHT. ANY OTHER
L9	COMMENTS?
20	DR. FONTANA: I JUST WANTED TO INFORM YOU
21	THAT I'VE BEEN WORKING CLOSELY WITH BERNIE SIEGEL
22	WHO IS PLANNING TO ANNOUNCE AT THE END OF THIS WEEK
23	A STEM CELL ACTION NETWORK. HE IS NOW REPRESENTING
24	A LARGE NUMBER OF PATIENT ADVOCATES GROUPS. AND ON
25	HIS WEB SITE HE IS GOING TO SUPPORT SORT OF THE

1	REPEALING OF THE DICKEY-WICKER AMENDMENT, AND HE'S
2	GOT QUITE A FEW GROUPS SIGNING ONTO THAT. THERE IS
3	A GROUNDSWELL, YOU MUST APPRECIATE THE GROUNDSWELL
4	AMONGST THE PATIENT COMMUNITIES TO WANT TO PUSH THIS
5	RESEARCH FORWARD. AND HOW THEY'RE DIRECTED, I
6	THINK, IS IMPORTANT, AS JOAN IS POINTING OUT. SO
7	I'D LIKE TO KEEP THAT IN OUR FOREFRONT AS WE
8	CONSTRUCT THIS MEMO.
9	CHAIRMAN TORRES: ALL RIGHT. THANK YOU
10	ALL FOR YOUR HELP AND YOUR PARTICIPATION TODAY. THE
11	SUBCOMMITTEE IS ADJOURNED.
12	(THE MEETING WAS THEN ADJOURNED AT
13	01:36 P.M.)
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	30

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE LEGISLATIVE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON MONDAY, NOVEMBER 8, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100